secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keenova Therapeutics plc (—)
CIK:        0001567892
Form:       8-K
Filed at:   2026-06-03T11:25:30+00:00
Accession:  0001104659-26-069792
Event type: regulatory
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Keenova shareholders elect all 9 director nominees, approve all proposals at annual meeting
--------------------------------------------------------------------------------

- All 9 director nominees elected to hold office until 2027 AGM; average ~25.2M votes 'For' per nominee.
- PricewaterhouseCoopers LLP re-appointed as independent auditor with 25.6M 'For' votes.
- Say-on-pay approved (25.0M 'For' vs 0.3M 'Against'); frequency set to 1 year.
- Special resolutions passed: capital reduction (25.3M 'For') and articles of association amendment (25.5M 'For').

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567892/000110465926069792/0001104659-26-069792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567892/000110465926069792/tm2616735d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-069792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer